Amendments to the Claims:

Please rewrite the claims as follows:

1. (Original) A drug delivery ophthalmic lens comprising a cationic group-containing drug in the inside of a copolymer consisting of a hydrophilic monomer having a hydroxyl group in its molecule, at least one member selected from phosphate group-containing methacrylates represented by the following structural formula (I), a monomer having a nitrogen atom in its side chain, and a monomer copolymerizable with these components,

formulae (I)

$$\begin{array}{c} \text{CH}_{3}\text{O} & \text{O} \\ \text{I} & \text{II} \\ \text{CH}_{2} = \text{C} - \text{C} - \text{O} + \text{CH}_{2} + \text{O} - \text{P} - \text{OH} \\ \text{OH} & \text{OH} \\ \end{array}$$

2. (Original) The drug delivery ophthalmic lens according to claim 1, wherein a mixture of the following structural formulae (II) and (III) is used as the phosphate group-containing methacrylates:

formulae (II)

formulae(III)

į

- 3. (Currently Amended) The drug delivery ophthalmic lens according to claim 1-or 2, wherein the content of the monomer having a nitrogen atom in its side chain is 0.05 to 40 wt%.
- 4. (Currently Amended) The drug delivery ophthalmic lens according to any one of elaims 1-to 3 claim 1, wherein the monomer having a nitrogen atom in its side chain is (meth)acrylamide.
- 5. (Currently Amended) The drug delivery ophthalmic lens according to any one of elaims 1 to 4 claim 1, wherein the cationic group-containing drug is an organic compound having at least one quaternary ammonium base or primary to tertiary amine base in its molecule.
- 6. (Original) A drug delivery ophthalmic lens comprising an anionic group-containing drug in the inside of a copolymer consisting of a hydrophilic monomer, cationic and anionic monomers, and a monomer copolymerizable with these components, wherein the copolymer contains the anionic monomer in a ratio of 30 to 90 mol% to the cationic monomer.
- 7. (Original) The drug delivery ophthalmic lens according to claim 6, wherein the anionic group-containing drug is an organic compound having at least one member selected from a carboxyl group, a sulfo group and a phosphate group in its molecule.
- 8. (Currently Amended) A solution for storing the drug delivery ophthalmic lens according to any one of claims 1 to 7 claim 6, which comprises a nonionic surfactant and a nonionic osmotic pressure regulating agent and is free of an ionic compound.
- 9. (Original) The storing solution according to claim 8, wherein the nonionic surfactant is a polyoxyethylene/polyoxypropylene nonionic surfactant (poloxamer type).
- 10. (Currently Amended) The storing solution according to claim 8-or-9, wherein the nonionic osmotic pressure regulating agent is propylene glycol or glycerin.